MBX BIOSCIENCES INC (MBX)
Sector: Health Care
2026 Annual Meeting Analysis
MBX BIOSCIENCES INC · Meeting: June 4, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Heron has served since July 2020 and has deep biotech investment experience as a Managing Partner at Frazier Life Sciences; MBX's 3-year stock return is +39% and the gap versus the XBI (SPDR S&P Biotech ETF) is -29.6 percentage points, which is well below the 65-percentage-point threshold required to trigger an AGAINST vote for a company with strong positive absolute returns, and all other policy screens (attendance, independence, overboarding) are clear.
Mathers has served since July 2020 and brings extensive biotech venture capital and executive experience at New Enterprise Associates and MedImmune; the same TSR analysis applies — MBX's -29.6 percentage-point gap versus XBI does not reach the 65-percentage-point trigger, and no other policy concerns are identified.
Both Class II nominees are independent directors with strong biotech industry credentials and long board tenures. MBX's 3-year absolute stock return of +39% places it in the strong-positive tier, requiring a gap of at least 65 percentage points versus XBI (SPDR S&P Biotech ETF) to trigger an AGAINST vote; the actual gap is only -29.6 percentage points, so the TSR trigger does not fire. All other policy screens — attendance (all directors met the 75% threshold), independence, overboarding, committee composition — are clear. Both directors receive a FOR vote.
Say on Pay
✓ FORCEO
P. Kent Hawryluk
Total Comp
N/A
Prior Support
N/A
MBX is an emerging growth company and has explicitly opted out of the advisory Say on Pay vote requirement — no formal Say on Pay proposal appears on this ballot, so this entry reflects the policy analysis of the compensation program as disclosed. CEO Hawryluk received total compensation of approximately $2.99 million in 2025, consisting of a $625,000 base salary, $1,998,092 in stock option awards (the reported value of stock options granted), and a $359,375 performance cash bonus, which is reasonable for a CEO of a $1.6 billion biotech company. The pay mix is well over 50% variable (roughly 79% of total pay is in equity awards and performance bonuses), the company has a formal clawback policy compliant with SEC and Nasdaq requirements, and bonuses are tied to clinical, R&D, and business development milestones — no structural concerns trigger a negative vote under policy.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
3 yrs
Audit Fees
$491,678
Non-Audit Fees
$0
Ernst & Young has audited MBX since 2023 (approximately 3 years), well below the 25-year tenure threshold; non-audit fees are zero, so there is no independence concern from non-audit work; and EY is a Big 4 firm appropriate for a $1.6 billion company — all policy screens are satisfied.
Overall Assessment
The 2026 MBX Biosciences annual meeting contains two formal proposals: election of two Class II directors and ratification of Ernst & Young as auditor. Both receive FOR votes — the directors clear all policy screens including the XBI TSR threshold, and Ernst & Young presents no fee, tenure, or independence concerns; there is no Say on Pay vote on the ballot as MBX has exercised its emerging growth company exemption, but a review of the disclosed compensation program finds no material concerns.